TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28933961

Group type: EXPERIMENTAL
Intervention: 17β-Estradiol (E2), 0.72 mg transdermally for 2-8 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 17β-Estradiol (E2), 0.62 mg and norethindrone acetate (P), 2.70 mg for 3-16 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Estra-1,3,5(10)-triene-3,16α, 17β-triol (E3) vaginal tablet 0.5 mg per month five times
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 58
Study: 25898050

Group type: EXPERIMENTAL
Intervention: Parent training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Parent education
Number of subjects: 180
Study: 23163714

Group type: EXPERIMENTAL
Intervention: Active manipulation group (AAT with contingency between arm movement and picture type)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (AAT without contingency)
Number of subjects: 0
Study: 21247563

Group type: EXPERIMENTAL
Intervention: Employed women
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nonworking women
Number of subjects: 132
Study: 18440921

Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (15 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16529577

Group type: EXPERIMENTAL
Intervention: Testogel (5 g containing 50 mg testosterone, daily) for 4 weeks, followed by tadalafil (20 mg, twice a week)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Testogel (5 g containing 50 mg testosterone, daily) for 10 weeks before adjunctive therapy with tadalafil
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Testogel and tadalafil combination therapy
Number of subjects: 69
Study: 14729656

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 801

Group type: COMPARATOR
Intervention: Control
Number of subjects: 801
Study: 11348940

Group type: EXPERIMENTAL
Intervention: Smokers with COPD
Number of subjects: 4035

Group type: COMPARATOR
Intervention: Healthy smokers
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: Both groups of smokers
Number of subjects: 4035
Study: 9236443

Group type: EXPERIMENTAL
Intervention: Dual-chamber rate-responsive pacemaker therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 107

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 107
Study: 7958108

Group type: EXPERIMENTAL
Intervention: ELISA for insulin antibodies (IA) in IDDM patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ELISA for insulin antibodies (IA) in NIDDM patients treated with insulin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ELISA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ELISA for insulin autoantibodies (IAA) in Graves' disease patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: RBA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: RBA for insulin autoantibodies (IAA) in Graves' disease patients
Number of subjects: 58
Study: 3309444

Group type: EXPERIMENTAL
Intervention: 3% Acyclovir eye ointment
Number of subjects: 28

Group type: COMPARATOR
Intervention: 3% Adenosine Arabinoside eye ointment
Number of subjects: 28
Study: 29067717

Group type: EXPERIMENTAL
Intervention: Haptic augmented skin surface generation with tactile mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual only interface
Number of subjects: 0
Study: 28007108

Group type: EXPERIMENTAL
Intervention: Contact lens group (n=54)
Number of subjects: 108

Group type: COMPARATOR
Intervention: IOL group (n=54)
Number of subjects: 108
Study: 23600695

Group type: EXPERIMENTAL
Intervention: Feedback provided on 0%, 50%, or 100% of the trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stacked presentations
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback provided during blocks 5 and 6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence ratings
Number of subjects: 0
Study: 23276775

Group type: EXPERIMENTAL
Intervention: Guided intervention (10 session workbook, 10 biweekly, 8 monthly, and 6 bimonthly phone coaching calls, bimonthly weight graphs, tailored letters)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Self-Directed intervention (workbook and two calls)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Guided intervention
Number of subjects: 419
Study: 19956091

Group type: EXPERIMENTAL
Intervention: Hemin (3 mg/kg intravenously in 25% albumin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (albumin alone)
Number of subjects: 10
Study: 19083412

Group type: EXPERIMENTAL
Intervention: Iron-fortified fermented milk beverage supplemented with Lactobacillus acidophilus (3 mg iron per 80 mL)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (fermented milk beverage without Lactobacillus acidophilus)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 190
Study: 16884986

Group type: EXPERIMENTAL
Intervention: Nonheparinized blood
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Heparinized blood
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: In vivo heparinization
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 12939317

Group type: EXPERIMENTAL
Intervention: Sodium lactate (0.6 mol/L)
Number of subjects: 12
Study: 10092890

Group type: EXPERIMENTAL
Intervention: Adjuvant arteriovenous fistula (AVF) included in the operative procedure (n = 48)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group without AVF (n = 41)
Number of subjects: 87
Study: 7747212

Group type: EXPERIMENTAL
Intervention: Latin American refugees
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: South European labour migrants
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: South Europeans
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Low social class, age 45-64 years, poor social network, not feeling secure in daily life, not taking regular exercise
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Finnish and Swedish controls
Number of subjects: 1623
Study: 2502437

Group type: EXPERIMENTAL
Intervention: hFSH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 20
Study: 3746

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D preparation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30943939

Group type: EXPERIMENTAL
Intervention: Interactive intervention group combining a website (STAK-D) and a PolarActive activity watch (PAW) alongside usual care
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 49
Study: 28363704

Group type: EXPERIMENTAL
Intervention: Interviewer-administered version of PM-3D4D
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Self-administered version of PM-3D4D
Number of subjects: 262
Study: 25031222

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: THC preceded by cognitive awareness condition
Number of subjects: 121
Study: 23691266

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg oral, 1 month before surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 21551996

Group type: EXPERIMENTAL
Intervention: Simulation-based education (including lecture, skill training, team-based practice, and debriefing)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional education (control group)
Number of subjects: 50
Study: 19411800

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) devices
Number of subjects: 43

Group type: COMPARATOR
Intervention: Knee and thigh length compression stockings (CS)
Number of subjects: 43
Study: 18236764

Group type: EXPERIMENTAL
Intervention: Integrated Chinese and Western medicine (ICWM) protocol
Number of subjects: 606

Group type: COMPARATOR
Intervention: Western medicine plus placebo
Number of subjects: 606
Study: 15545307

Group type: EXPERIMENTAL
Intervention: 200 mg R411 as a single oral dose
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 100 mg RO0270608 as an intravenous infusion
Number of subjects: 132

Group type: COMPARATOR
Intervention: Single oral doses of R411 (10-1200 mg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Repeated oral doses of R411 (50-900 mg) for up to 3 weeks
Number of subjects: 132
Study: 11396759

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation (EBD)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 180
Study: 9893692

Group type: EXPERIMENTAL
Intervention: Improved blood glucose control
Number of subjects: 5102
Study: 8289475

Group type: EXPERIMENTAL
Intervention: ETI (Etoposide 80 mg/m2, Thioguanine 100 mg/m2 twice a day on days 1-5, Idarubicin 15 mg/m2 on days 1-3)
Number of subjects: 51

Group type: COMPARATOR
Intervention: TAD (Oral Thioguanine 100 mg/m2 twice a day on days 1-5, i.v. Cytarabine, Daunorubicin 60 mg/m2 on day 5)
Number of subjects: 51
Study: 3301058

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of streptokinase
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional treatment in the coronary care unit
Number of subjects: 533
Study: 29661905

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27475737

Group type: EXPERIMENTAL
Intervention: Rapid determination of methicillin resistance using real-time PCR
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group without PCR results
Number of subjects: 89
Study: 24897083

Group type: EXPERIMENTAL
Intervention: Oritavancin (1200 mg single intravenous dose)
Number of subjects: 954

Group type: COMPARATOR
Intervention: Vancomycin (twice daily for 7 to 10 days)
Number of subjects: 954
Study: 22240281

Group type: EXPERIMENTAL
Intervention: Acupuncture at LI4
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Acupuncture at LI4 (subgroup of 13 participants)
Number of subjects: 98
Study: 20552165

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 149
Study: 18388226

Group type: EXPERIMENTAL
Intervention: Ionization smoke alarms
Number of subjects: 761

Group type: COMPARATOR
Intervention: Photoelectric smoke alarms
Number of subjects: 761
Study: 18349181

Group type: EXPERIMENTAL
Intervention: Oral ondansetron disintegrating tablets (ODT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 15224055

Group type: EXPERIMENTAL
Intervention: Maxillary protractor bow appliance (MPBA) used for a mean period of 5 months in the DT group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Maxillary protractor bow appliance (MPBA) used for a mean period of 10 months in the MT group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 120
Study: 11320369

Group type: EXPERIMENTAL
Intervention: Eprosartan (400 to 800 mg daily)
Number of subjects: 36
Study: 10322821

Group type: EXPERIMENTAL
Intervention: Kangaibao oral liquid (KABOL)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 103
Study: 8494577

Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trospium chloride 40 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trospium chloride 80 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trospium chloride 120 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trospium chloride 180 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trospium chloride 240 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trospium chloride 360 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3115081

Group type: EXPERIMENTAL
Intervention: Oligosaccharides infusion (144 +/- 41.0 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no oligosaccharides)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oligosaccharides infusion
Number of subjects: 14
Study: 30417279

Group type: EXPERIMENTAL
Intervention: Apremilast (n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study: 27846922

Group type: COMPARATOR
Intervention: Brexpiprazole (2 mg, 4 mg) in short-term fixed-dose studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole (2-4 mg) in flexible-dose short-term study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole in maintenance study (1-4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole in all studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brexpiprazole in short-term studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole overall
Number of subjects: 0
Study: 25829142

Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23837527

Group type: EXPERIMENTAL
Intervention: Postcard intervention (handwritten messages and seasonal reports sent once a month for eight consecutive months)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Postcard intervention
Number of subjects: 180
Study: 22104978

Group type: EXPERIMENTAL
Intervention: Training sessions by a physical therapist and an empowerment trainer, and a Rest‐Break Tool
Number of subjects: 171
Study: 20005355

Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression regimen with 80% reduction of cyclosporine or tacrolimus (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression regimen with discontinuation of cyclosporine or tacrolimus (group 2)
Number of subjects: 20
Study: 16430956

Group type: EXPERIMENTAL
Intervention: Photo-cured cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemically cured cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-cured cements
Number of subjects: 0
Study: 14704238

Group type: EXPERIMENTAL
Intervention: Intracervical placement of dinoprostone (n = 24)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intracervical placement of dinoprostone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Posterior fornix placement of dinoprostone (n = 22)
Number of subjects: 63
Study: 11703236

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel (Harmonic scalpel)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy
Number of subjects: 32
Study: 9153737

Group type: EXPERIMENTAL
Intervention: N-9 vaginal gel (Advantage-24), 52.5 mg, applied once daily for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel, applied once daily for 2 weeks
Number of subjects: 60
Study: 8423760

Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen (400 mg TID initiated 4 h before exercise)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Therapeutic ibuprofen (400 mg TID initiated 24 h after baseline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prophylactic and therapeutic ibuprofen
Number of subjects: 20
Study: 3688278

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Neuroleptic withdrawal
Number of subjects: 19
Study: 31595954

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 53454

Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 53454

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) with prior AAD
Number of subjects: 53454
Study: 28851132

Group type: EXPERIMENTAL
Intervention: Intervention group (nursing assistant supervised home exercise programme)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 148
Study: 27213789

Group type: EXPERIMENTAL
Intervention: LAGB plus anterior fundoplication (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: LAGB alone (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24615684

Group type: EXPERIMENTAL
Intervention: Educational/motivational intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual clinical information (Control)
Number of subjects: 62
Study: 22329591

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-5 mg plus amiloride/hydrochlorothiazide 1.25-2.5 mg/12.5-25 mg (Group A)
Number of subjects: 13542

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-5 mg plus telmisartan 40-80 mg (Group T)
Number of subjects: 13542
Study: 20520286

Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 18772451

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (nonwake-up group)
Number of subjects: 43
Study: 15625265

Group type: EXPERIMENTAL
Intervention: BURP maneuver with cricoid pressure
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cricoid pressure alone
Number of subjects: 43

Group type: COMPARATOR
Intervention: No pressure
Number of subjects: 43
Study: 12196749

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed twice daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed once daily
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed 5 times a week
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream dosed 3 times a week
Number of subjects: 128

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 128
Study: 10197891

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 7760888

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg per day for 48 hours)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2328197

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg 12 hourly
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg 12 hourly
Number of subjects: 9
Study: 85937

Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg/day combined with propranolol 80 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31286480

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 205
Study: 31746775

Group type: EXPERIMENTAL
Intervention: Hygie (serious game)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Reading (traditional method)
Number of subjects: 269
Study: 28889847

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-laser acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical symptom control
Number of subjects: 0
Study: 26433717

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing 0.4% rice peptide CL(14-25)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 10
Study: 23657005

Group type: EXPERIMENTAL
Intervention: Transglucosidase (TGD) 300 or 900 mg/day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21851461

Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressant
Number of subjects: 31
Study: 19111223

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17239888

Group type: EXPERIMENTAL
Intervention: Atorvastatin/Niacin ER
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Niacin ER
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe
Number of subjects: 292

Group type: COMPARATOR
Intervention: Rosuvastatin alone
Number of subjects: 292
Study: 15523985

Group type: EXPERIMENTAL
Intervention: Alcon CustomCornea
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bausch & Lomb Zyoptix
Number of subjects: 30
Study: 11177313

Group type: EXPERIMENTAL
Intervention: Prednisone and Methotrexate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9428879

Group type: EXPERIMENTAL
Intervention: 2.0 micrograms/kg clonidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7699537

Group type: EXPERIMENTAL
Intervention: Immunization tracking system
Number of subjects: 597

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 597
Study: 2546778

Group type: EXPERIMENTAL
Intervention: Chemotherapy (etoposide, doxorubicin, methotrexate (VAM) and procarbacine, vincristine, cyclophosphamide, lomustine (POCC) with prophylactic cranial irradiation (30 Gy))
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sequential hemibody irradiation (SHBI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Local and/or locoregional radiotherapy
Number of subjects: 99
Study: 612628

Group type: EXPERIMENTAL
Intervention: Tinidazole, 50 mg/kg once
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole, 50 mg/kg once
Number of subjects: 60
Study: 31747959

Group type: EXPERIMENTAL
Intervention: abPI‐VSD (antibiotic-containing drainage fluid)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antibiotic irrigation solution without abPI‐VSD
Number of subjects: 75